Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Stock Information for Enveric Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enveric Biosciences Inc.

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.